Spark Biomedical

Open enrollment across a mixed-phase pipeline

According to ClinicalTrials.gov-derived indexes, Spark Biomedical sits in the top decile of US sponsors by registered trial count (#1,049 of 15,742 sponsors by registered trial count).

13 total trials 4 currently recruiting 8 completed top decile by trial count

Spark Biomedical: 13 sponsored US clinical trials, 4 recruiting.

Spark Biomedical sponsors 13 registered US clinical trials on ClinicalTrials.gov, 4 of them currently recruiting, and 8 completed. The most-studied condition in this pipeline is Opioid Withdrawal, with 2 trials.

Top-decile sponsor footprint

Spark Biomedical ranks in the top decile of sponsors by registered trial count (#1,049 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.

Open and recent trials

13 total, page 1 of 1

RECRUITING NA

Delivering tAN to Reduce HMB: The LUNA Study

NCT07326722
RECRUITING NA

tAN for Substance Use Disorder

NCT07281261
RECRUITING NA

tAN for First Responders

NCT07109349
RECRUITING

Sensing Physiological Symptoms of Opioid Withdrawal and Cravings in Patients With Opioid Use Disorder

NCT06487533
ACTIVE NOT RECRUITING NA

Neurostimulation to Improve NOWS Outcomes

NCT05129020
COMPLETED NA

Transcutaneous Auricular Neurostimulation as a Treatment for Women With Heavy Menstrual Bleeding: A Dose-finding Trial

NCT06814028
COMPLETED NA

Effect of Transcutaneous Auricular Neurostimulation on Cognitive Performance in a Laboratory Model of Acute Stress Reaction

NCT06390267
COMPLETED NA

Delivering Transcutaneous Auricular Neurostimulation to Regulate Platelet Activity in Healthy Human Subjects

NCT05977946
COMPLETED

Clinical Outcomes Following Transcutaneous Auricular Neurostimulation to Improve Relapse Prevention: A Long-term Follow-up Study

NCT05591703
COMPLETED NA

Delivering Transcutaneous Auricular Neurostimulation to Improve Relapse Prevention in Opioid Use Disorder

NCT05053503
COMPLETED NA

Novel Earpiece for Transcutaneous Auricular Neurostimulation (tAN) for Symptoms of Opioid Withdrawal

NCT04731935
COMPLETED NA

tAN to Mitigate Withdrawal Behaviors in Neonates

NCT04588519
COMPLETED NA

Transcutaneous Auricular Neurostimulation (tAN) for Symptoms of Opioid Withdrawal

NCT04075214

Therapeutic Areas

Opioid Withdrawal 2
Opioid Use Disorder 2
Blood Biomarkers 1
Neonatal Abstinence Syndrome 1
Heavy Menstrual Bleeding 1
Hemostasis 1
Neonatal Opioid Withdrawal Syndrome 1
Mental Stress 1
Mental Fatigue 1

What is open in the Spark Biomedical pipeline

4 recruiting of 13 indexed (31% open); 8 completed (62%).

Phase labels are sparse on this sponsor index, so phase mix is not charted here.

Top condition: Opioid Withdrawal (2 trials), 8 others listed.

How open-pipeline share is computed

Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.

Spark Biomedical: open-pipeline peers nationwide

Peers matched on 13 registered trials and 31% open enrollment, not the therapeutic-area sidebar.

Spark Biomedical sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot). 2×2 strategic matrix plotting 9 entities by Total trials (X) and Recruiting share (Y), with a crosshair dividing the plot into four quadrants. Higher volume & more openFocused & more openHigher volume, mostly closedSmaller & mostly closed 1020304050 0%10%20%30%40% Total trials Recruiting share Spark BiomedicalAdaptimmuneAgennixAkili Interactive LabsAlumisFoundation for Orthopaedic Research and EducationLaureate Institute for Brain ResearchPhilips Clinical & Medical Affairs GlobalEko Devices
Spark Biomedical sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot).

Spark Biomedical sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.

Sponsors near 13 trials (± recruiting share)

Sponsors near 31% open enrollment (± trial volume)

Related

Read our methodology - how this data is sourced, computed, and verified.

What to do with this Spark Biomedical page

13 registered trials is a research-attention snapshot, not an endorsement of Spark Biomedical or any single study.

  • 4 of Spark Biomedical's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
  • Opioid Withdrawal is the condition Spark Biomedical studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Opioid Withdrawal trials
  • Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. Spark Biomedical pipeline card: 13 registered trials from official public datasets. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.